Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:27:38.412Z.
Calculation as of: 2026-10-06T18:27:38.412Z.
Quote observation: 2026-10-06T18:25:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 82cee4a6010f8650e239c44e6fa86f6cad5a1cacb0b867e980d6d40a64789328
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$234.54M
EBITDA Yield
N/A
TTM Avg
22.77%
3Y Avg
22.51%
5Y Avg
19.57%
Market Cap
$235.97M
EBITDA Yield
5.37%
TTM Avg
11.46%
3Y Avg
13.23%
5Y Avg
11.81%
Market Cap
$236.67M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$237.27M
EBITDA Yield
N/A
TTM Avg
6.75%
3Y Avg
3.64%
5Y Avg
3.64%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Nautilus Biotechnolgy, Inc. (NAUT) | $234.79M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $234.93M | N/A | N/A | N/A | N/A |
| SIGA Technologies, Inc. (SIGA)vs › | $234.54M | N/A | 22.77% | 22.51% | 19.57% |
| Utah Medical Products, Inc. (UTMD)vs › | $235.97M | 5.37% | 11.46% | 13.23% | 11.81% |
| BioAge Labs Inc. (BIOA)vs › | $231.55M | N/A | N/A | N/A | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $236.67M | N/A | N/A | N/A | N/A |
| Akebia Therapeutics, Inc. (AKBA)vs › | $237.27M | N/A | 6.75% | 3.64% | 3.64% |
| High Tide Inc. (HITI)vs › | $237.69M | 7.80% | 5.41% | 5.10% | 3.84% |
| MacroGenics, Inc. (MGNX)vs › | $231.69M | N/A | 0.97% | 0.50% | 0.50% |
| Biodesix, Inc. (BDSX)vs › | $229.96M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
